Abstract:Esophageal carcinoma (EC) ranks among the top six most prevalent malignancies worldwide with a recent surge in incidence. An innovative integrated omics technique is presented for discerning the two primary types of esophageal carcinoma (EC) AND Squamous cell carcinoma and adenocarcinoma. Utilizing The Cancer Genome Atlas (TCGA) data via Bioconductor, the research integrated DNA methylation and RNA expression analyses for esophageal cancer (ESCA). Key findings revealed DNA methylation’s pivotal role in ESCA progression and its potential as an early detection biomarker. Significant disparities in methylation patterns offered insights into the disease’s pathogenesis. A comparison with the TCGA Pan-Cancer dataset using Bioconductor tools enriched the understanding of ESCA genomics. Specifically, 131,220 hypomethylated probes were detected in tumors compared to 6,248 in healthy tissues. Additionally, 42,060 probe-gene pairs linked methylation variations to expression alterations, with 768 hypomethylated motifs identified. Thirteen of these motifs emerged as potential diagnostic markers. Transcription factor analyses spotlighted crucial regulators, including NFL3, ATF4, JUN, and CEBPG, revealing intricate regulatory networks in ESCA. Survival statistics further correlated clinical factors with patient longevity. This research recommends an innovative approach to identifying oesophageal abnormalities through DNA methylation and gene expression mechanisms. Research suggests DNA methylation may serve as an early detection biomarker, aiding in identifying esophagus cancer prior to more advanced stages. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial "N/A" ### Clinical Protocols ### Funding Statement The work is self funded. my country blongs to group B global assistant program. I am the author of the manucript and i will apply for research group which will cover all the publication fee. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Our research adhered to high ethical standards, having received approval from the Institutional Review Board (IRB). This work was supported by the Liaoning Province Rejuvenating Talents Plan (No: XLYC2002045), the Key R&D Program of Liaoning Province (No: 2019JH2/10300041), Scientific Research Project from the Department of Education of Liaoning Province (No. LJKZ0088 and LQN201906), the National Natural Science Foundation of China (No: 82003655) and Shenyang Science and Technology Project (No. 21-116-3-48 and RC210216). The research did not entail any conflicts of interest and all financial support. The data collected during this study will be made available upon request, following the guidelines set by MedRxiv for data sharing. Each author contributed significantly to the execution of this research and the preparation of the manuscript, underlining a collective commitment to ethical research and reporting practices. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Upon the acceptance of this manuscript for publication, the supporting data and associated code will be made publicly available on GitHub for the benefit of the research community. Interested researchers can access these resources at the following repository: .

Abstract 757: Integrating microbiome analysis and multi-modal data to identify high-risk population for esophageal adenocarcinoma

Resident Esophageal Microbiota Dysbiosis Correlates with Cancer Risk in Barrett's Esophagus Patients and Is Linked to Low Adherence to WCRF/AICR Lifestyle Recommendations

Global Metabolic Profiling Identifies Novel Serum Markers For Esophageal Adenocarcinoma

Abstract 5587: Personalized Risk Prediction Tool for Esophageal Adenocarcinoma in Caucasian Population

Abstract 3604: Identification of genes involved in pathogenesis of esophageal adenocarcinoma using RNA sequencing from laser capture micro-dissected formalin-fixed paraffin-embedded tissue specimens

Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma

Abstract 5910: Prospective Platform to Define Microbiome Correlates of Metastasis and Therapy Resistance in Early Onset and Average Onset Gastrointestinal Cancers

Abstract LB249: Multi-omics cancer risk assessment of Barrett's esophagus with DNA methylation sequencing from endoscopic brush samples

The Salivary Microbiome and Predicted Metabolite Production are Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma

Model for Identifying Individuals at Risk for Esophageal Adenocarcinoma

Abstract 6853: Spatial proteomic and transcriptomic characterization of the inflammatory landscape of formalin fixed paraffin embedded Barrett’s esophagus tissues

Abstract 1679: Genome-wide Methylation Analysis in Barrett's Esophagus and Esophageal Adenocarcinoma

Oral microbiota may predict the presence of esophageal squamous cell carcinoma

The Salivary Microbiome and Predicted Metabolite Production Are Associated with Barrett's Esophagus and High-Grade Dysplasia or Adenocarcinoma

Unlocking Esophageal Carcinoma’s Secrets: an Integrated Omics Approach Unveils DNA Methylation As a Pivotal Early Detection Biomarker with Clinical Implications

Abstract 238: Evidence of Early Colorectal Cancer Risk and Prevention Pathways in the Fecal Microbiome of Colonoscopy Patients: Associations with Diet and Circulating Adipocytokines

Abstract 3890: Comprehensive molecular and immunological characterization of early-onset esophagogastric cancer

Molecular biomarker identification for esophageal adenocarcinoma using endoscopic brushing and magnified endoscopy

The Role of Microbiota in the Pathogenesis of Esophageal Adenocarcinoma

Novel Epigenetic Network Biomarkers for Early Detection of Esophageal Cancer.

Supplementary Information from Oral Microbiome Composition Reflects Prospective Risk for Esophageal Cancers